Dilated Cardiomyopathy Market By Drug Class, Device and Distribution Channel - Global Industry Analysis And Forecast To 2025

Published On : November 2018 Pages : 180 Category: Pharmaceuticals Report Code : HC111675

Dilated Cardiomyopathy Market By Drug Class (Cardiac Glycosides, Beta Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, Blood Thinning Medications, Diuretics & Angiotensin II Receptor Blockers), Device (Heart Pumps, Cardioverter-Defibrillators & Implantable Devices) and Distribution Channel (Hospital Pharmacies, Mail Order Pharmacies, Retails Pharmacies & Online Pharmacies) - Global Industry Analysis And Forecast To 2025              

Industry Outlook

Dilated Cardiomyopathy (DCM) is a phase of heart in which the blood pumping capacity of heart is reduced as the primary pumping chamber (left ventricle) of heart is weakened and enlarged. In other cases the heart is prevented from filling with blood & relaxing as in normal functioning. If this condition is not treated it affects other chambers over a period of time. Dilated Cardiomyopathy treatment growth is due to factors like; rising number of cases related to congestive heart failure, also rising life anticipation, etc. Therefore, the Dilated Cardiomyopathy Market is anticipated to expand and has tremendous scope during the forecast period. The global Dilated Cardiomyopathy Market anticipated to flourish in the future by growing at a significantly higher CAGR.

Market Segmentation

The global Dilated Cardiomyopathy Market is based on segment, by Drug Class the market is segmented into Cardiac Glycosides, Beta Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, Blood Thinning Medications, Diuretics & Angiotensin II Receptor Blockers, by Device the market is segmented into Heart Pumps, Cardioverter-Defibrilators & Implantable Devices and by Distribution Channel the market is segmented into Hospital Pharmacies, Mail Order Pharmacies, Retails Pharmacies & Online Pharmacies.

  • Dilated Cardiomyopathy Market, By Drug Class
  • Cardiac Glycosides
  • Beta Blockers
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Blood Thinning Medications
  • Diuretics
  • Angiotensin II Receptor Blockers
  • Dilated Cardiomyopathy Market, By Device
  • Heart Pumps
  • Cardioverter-Defibrilators
  • Implantable Devices
  • Dilated Cardiomyopathy Market, By Distribution Channel
  • Hospital Pharmacies
  • Mail Order Pharmacies
  • Retails Pharmacies
  • Online Pharmacies

Regional Insights

On a global front, the Dilated Cardiomyopathy Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA). North American region leads the Dilated Cardiomyopathy Market due to factors like; increasing cases of congestive failures of heart.

Dilated Cardiomyopathy Market, By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis

The leading players in the market are Johnson and Johnson, Merck & Co. Inc., Zensun Sci & tech, Capricor Therapeutics, Sanofi, Teva Pharmaceuticals, Array BioPharma, Aastrom Biosciences, Vericel Corporation, t2cure GmbH, MyoKardia, GlaxoSmithKline plc, Kasiak Research Pvt. Ltd., Pfizer Inc., Astrazeneca plc. and PhaseBio Pharmaceuticals. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.

  • Johnson and Johnson
  • Merck & Co. Inc.
  • Zensun Sci & tech
  • Capricor Therapeutics
  • Sanofi
  • Teva Pharmaceuticals
  • Array BioPharma
  • Aastrom Biosciences
  • Vericel Corporation
  • t2cure GmbH
  • MyoKardia
  • GlaxoSmithKline plc.
  • Kasiak Research Pvt. Ltd.
  • Pfizer Inc.
  • Astrazeneca plc.
  • PhaseBio Pharmaceuticals

Some of the key questions answered by the report are:          

  • What was the market size in 2014 and forecast from 2015 to 2025?
  • What will be the industry market growth from 2015 to 2025?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

o   Dilated Cardiomyopathy Market, By Drug Class, Estimates and Forecast, 2014-2025 ($Million)

o   Cardiac Glycosides

o   Beta Blockers

o   Angiotensin-Converting Enzyme (ACE) Inhibitors

o   Blood Thinning Medications

o   Diuretics

o   Angiotensin II Receptor Blockers

o   Dilated Cardiomyopathy Market, By Device, Estimates and Forecast, 2014-2025 ($Million)

o   Heart Pumps

o   Cardioverter-Defibrillators

o   Implantable Devices

o   Dilated Cardiomyopathy Market, By Distribution Channel, Estimates and Forecast, 2014-2025 ($Million)

o   Hospital Pharmacies

o   Mail Order Pharmacies

o   Retails Pharmacies

o   Online pharmacies

o   Dilated Cardiomyopathy Market, By Region, Estimates and Forecast, 2014-2025 ($Million)

o   North America

§  North America Dilated Cardiomyopathy Market, By Country

o   U.S. Dilated Cardiomyopathy Market

o   Canada Dilated Cardiomyopathy Market

o   Mexico Dilated Cardiomyopathy Market

o   Europe

§  Europe Dilated Cardiomyopathy Market, By Country

o   Germany Dilated Cardiomyopathy Market

o   UK Dilated Cardiomyopathy Market

o   France Dilated Cardiomyopathy Market

o   Russia Dilated Cardiomyopathy Market

o   Italy Dilated Cardiomyopathy Market

o   Rest of Europe Dilated Cardiomyopathy Market

o   Asia-Pacific

§  Asia-Pacific Dilated Cardiomyopathy Market, By Country

o   China Dilated Cardiomyopathy Market

o   Japan Dilated Cardiomyopathy Market

o   South Korea  Dilated Cardiomyopathy Market

o   India Dilated Cardiomyopathy Market

o   Southeast Asia Dilated Cardiomyopathy Market

o   Rest of Asia-Pacific Dilated Cardiomyopathy Market

o   South America

§  South America Dilated Cardiomyopathy Market, By Country

o   Brazil Dilated Cardiomyopathy Market

o   Argentina Dilated Cardiomyopathy Market

o   Columbia Dilated Cardiomyopathy Market

o   Rest of South America Dilated Cardiomyopathy Market

o   Middle East and Africa

§  Middle East and Africa Dilated Cardiomyopathy Market, By Country

o   Saudi Arabia Dilated Cardiomyopathy Market

o   UAE Dilated Cardiomyopathy Market

o   Egypt Dilated Cardiomyopathy Market

o   Nigeria Dilated Cardiomyopathy Market

o   South Africa Dilated Cardiomyopathy Market

o   Rest of MEA Dilated Cardiomyopathy Market

Table of Contents

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2014-2025)

4.1.2.  Canada Market Status and Outlook (2014-2025)

4.1.3.  Mexico Market Status and Outlook (2014-2025)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2014-2025)

4.2.2.  France Market Status and Outlook (2014-2025)

4.2.3.  UK Market Status and Outlook (2014-2025)

4.2.4.  Russia Market Status and Outlook (2014-2025)

4.2.5.  Italy Market Status and Outlook (2014-2025)

4.2.6.  Rest of Europe Market Status and Outlook (2014-2025)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2014-2025)

4.3.2.  Japan Market Status and Outlook (2014-2025)

4.3.3.  Korea Market Status and Outlook (2014-2025)

4.3.4.  India Market Status and Outlook (2014-2025)

4.3.5.  Southeast Asia Market Status and Outlook (2014-2025)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2014-2025)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2014-2025)

4.4.2.  Argentina Market Status and Outlook (2014-2025)

4.4.3.  Columbia Market Status and Outlook (2014-2025)

4.4.4.  Rest of South America Market Status and Outlook (2014-2025)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2014-2025)

4.5.2.  United Arab Emirates Market Status and Outlook (2014-2025)

4.5.3.  Egypt Market Status and Outlook (2014-2025)

4.5.4.  Nigeria Market Status and Outlook (2014-2025)

4.5.5.  South Africa Market Status and Outlook (2014-2025)

4.5.6.  Turkey Market Status and Outlook (2014-2025)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2014-2025)

5.       Dilated Cardiomyopathy Market, By Drug Class

5.1.     Introduction

5.2.     Global Dilated Cardiomyopathy Revenue and Market Share by Drug Class (2014-2018)

5.2.1.  Global Dilated Cardiomyopathy Revenue and Revenue Share by Drug Class (2014-2018)

5.3.     Cardiac Glycosides

5.3.1.  Global Cardiac Glycosides Revenue and Growth Rate (2014-2018)

5.4.     Beta Blockers

5.4.1.  Global Beta Blockers Revenue and Growth Rate (2014-2018)

5.5.     Angiotensin-Converting Enzyme (ACE) Inhibitors

5.5.1.  Global Angiotensin-Converting Enzyme (ACE) Inhibitors Revenue and Growth Rate (2014-2018)

5.6.     Blood Thinning Medications

5.6.1.  Global Blood Thinning Medications Revenue and Growth Rate (2014-2018)

5.7.     Diuretics

5.7.1.  Global Diuretics Revenue and Growth Rate (2014-2018)

5.8.     Angiotensin II Receptor Blockers

5.8.1.  Global Angiotensin II Receptor Blockers Revenue and Growth Rate (2014-2018)

6.       Dilated Cardiomyopathy Market, By Device

6.1.     Introduction

6.2.     Global Dilated Cardiomyopathy Revenue and Market Share by Device (2014-2018)

6.2.1.  Global Dilated Cardiomyopathy Revenue and Revenue Share by Device (2014-2018)

6.3.     Heart Pumps

6.3.1.  Global Heart Pumps Revenue and Growth Rate (2014-2018)

6.4.     Cardioverter-Defibrilators

6.4.1.  Global Cardioverter-Defibrilators Revenue and Growth Rate (2014-2018)

6.5.     Implantable Devices

6.5.1.  Global Implantable Devices Revenue and Growth Rate (2014-2018)

7.       Dilated Cardiomyopathy Market, By Distribution Channel

7.1.     Introduction

7.2.     Global Dilated Cardiomyopathy Revenue and Market Share by Distribution Channel (2014-2018)

7.2.1.  Global Dilated Cardiomyopathy Revenue and Revenue Share by Distribution Channel (2014-2018)

7.3.     Hospital Pharmacies

7.3.1.  Global Hospital Pharmacies Revenue and Growth Rate (2014-2018)

7.4.     Mail Order Pharmacies

7.4.1.  Global Mail Order Pharmacies Revenue and Growth Rate (2014-2018)

7.5.     Retails Pharmacies

7.5.1.  Global Retails Pharmacies Revenue and Growth Rate (2014-2018)

7.6.     Online Pharmacies

7.6.1.  Global Online Pharmacies Revenue and Growth Rate (2014-2018)

8.       Dilated Cardiomyopathy Market, By Region

8.1.     Introduction

8.2.     Global Dilated Cardiomyopathy Revenue and Market Share by Regions

8.2.1.  Global Dilated Cardiomyopathy Revenue by Regions (2014-2018)

8.3.     North America Dilated Cardiomyopathy by Countries

8.3.1.  North America Dilated Cardiomyopathy Revenue and Growth Rate (2014-2018)

8.3.2.  North America Dilated Cardiomyopathy Revenue (Million USD) by Countries (2014-2018)

8.3.3.  United States

8.3.3.1. United States Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.3.4.  Canada

8.3.4.1. Canada Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.3.5.  Mexico

8.3.5.1. Mexico Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.     Europe Dilated Cardiomyopathy by Countries

8.4.1.  Europe Dilated Cardiomyopathy Revenue and Growth Rate (2014-2018)

8.4.2.  Europe Dilated Cardiomyopathy Revenue (Million USD) by Countries (2014-2018)

8.4.3.  Germany

8.4.3.1. Germany Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.4.  France

8.4.4.1. France Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.5.  UK

8.4.5.1. UK Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.6.  Russia

8.4.6.1. Russia Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.7.  Italy

8.4.7.1. Italy Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.8.  Rest of Europe

8.4.8.1. Rest of Europe Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.     Asia-Pacific Dilated Cardiomyopathy by Countries

8.5.1.  Asia-Pacific Dilated Cardiomyopathy Revenue and Growth Rate (2014-2018)

8.5.2.  Asia-Pacific Dilated Cardiomyopathy Revenue (Million USD) by Countries (2014-2018)

8.5.3.  China

8.5.3.1. China Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.4.  Japan

8.5.4.1. Japan Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.5.  Korea

8.5.5.1. Korea Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.6.  India

8.5.6.1. India Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.7.  Southeast Asia

8.5.7.1. Southeast Asia Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.8.  Rest of Asia-Pacific

8.5.8.1. Rest of Asia-Pacific Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.6.     South America Dilated Cardiomyopathy by Countries

8.6.1.  South America Dilated Cardiomyopathy Revenue and Growth Rate (2014-2018)

8.6.2.  South America Dilated Cardiomyopathy Revenue (Million USD) by Countries (2014-2018)

8.6.3.  Brazil

8.6.3.1. Brazil Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.6.4.  Argentina

8.6.4.1. Argentina Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.6.5.  Columbia

8.6.5.1. Columbia Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.6.6.  Rest of South America

8.6.6.1. Rest of South America Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.     Middle East and Africa Dilated Cardiomyopathy by Countries

8.7.1.  Middle East and Africa Dilated Cardiomyopathy Revenue and Growth Rate (2014-2018)

8.7.2.  Middle East and Africa Dilated Cardiomyopathy Revenue (Million USD) by Countries (2014-2018)

8.7.3.  Saudi Arabia

8.7.3.1. Saudi Arabia Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.4.  United Arab Emirates

8.7.4.1. United Arab Emirates Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.5.  Egypt

8.7.5.1. Egypt Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.6.  Nigeria

8.7.6.1. Nigeria Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.7.  South Africa

8.7.7.1. South Africa Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.8.  Turkey

8.7.8.1. Turkey Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.9.  Rest of Middle East and Africa

8.7.9.1. Rest of Middle East and Africa Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

9.       Company Profiles

9.1.     Johnson and Johnson

9.1.1.  Business Overview

9.1.2.   Service Portfolio

9.1.3.  Strategic Developments

9.1.4.   Revenue and Market Share

9.2.     Merck & Co. Inc.

9.2.1.  Business Overview

9.2.2.   Service Portfolio

9.2.3.  Strategic Developments

9.2.4.   Revenue and Market Share

9.3.     Zensun Sci & tech

9.3.1.  Business Overview

9.3.2.   Service Portfolio

9.3.3.  Strategic Developments

9.3.4.   Revenue and Market Share

9.4.     Capricor Therapeutics

9.4.1.  Business Overview

9.4.2.   Service Portfolio

9.4.3.  Strategic Developments

9.4.4.   Revenue and Market Share

9.5.     Sanofi

9.5.1.  Business Overview

9.5.2.   Service Portfolio

9.5.3.  Strategic Developments

9.5.4.   Revenue and Market Share

9.6.     Teva Pharmaceuticals

9.6.1.  Business Overview

9.6.2.   Service Portfolio

9.6.3.  Strategic Developments

9.6.4.   Revenue and Market Share

9.7.     Array BioPharma

9.7.1.  Business Overview

9.7.2.   Service Portfolio

9.7.3.  Strategic Developments

9.7.4.   Revenue and Market Share

9.8.     Aastrom Biosciences

9.8.1.  Business Overview

9.8.2.   Service Portfolio

9.8.3.  Strategic Developments

9.8.4.   Revenue and Market Share

9.9.     Vericel Corporation

9.9.1.  Business Overview

9.9.2.   Service Portfolio

9.9.3.  Strategic Developments

9.9.4.   Revenue and Market Share

9.10. t2cure GmbH

9.10.1.      Business Overview

9.10.2.       Service Portfolio

9.10.3.      Strategic Developments

9.10.4.       Revenue and Market Share

9.11. MyoKardia

9.11.1.      Business Overview

9.11.2.       Service Portfolio

9.11.3.      Strategic Developments

9.11.4.       Revenue and Market Share

9.12. GlaxoSmithKline plc.

9.12.1.      Business Overview

9.12.2.       Service Portfolio

9.12.3.      Strategic Developments

9.12.4.       Revenue and Market Share

9.13. Kasiak Research Pvt. Ltd.

9.13.1.      Business Overview

9.13.2.       Service Portfolio

9.13.3.      Strategic Developments

9.13.4.       Revenue and Market Share

9.14. Pfizer Inc.

9.14.1.      Business Overview

9.14.2.       Service Portfolio

9.14.3.      Strategic Developments

9.14.4.       Revenue and Market Share

9.15. Astrazeneca plc.

9.15.1.      Business Overview

9.15.2.       Service Portfolio

9.15.3.      Strategic Developments

9.15.4.       Revenue and Market Share

9.16. PhaseBio Pharmaceuticals

9.16.1.      Business Overview

9.16.2.       Service Portfolio

9.16.3.      Strategic Developments

9.16.4.       Revenue and Market Share

10.    Global Dilated Cardiomyopathy Market Competition, by Manufacturer

10.1. Global Dilated Cardiomyopathy Revenue and Market Share by Manufacturer (2016-2017)

10.2. Global Dilated Cardiomyopathy Price By Region (2016-2017)

10.3. Top 5 Dilated Cardiomyopathy Manufacturer Market Share

10.4. Market Competition Trend

11.    Dilated Cardiomyopathy Market Forecast (2018-2025)

11.1. Global Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2018-2025)

11.2. Dilated Cardiomyopathy Market Forecast by Regions (2018-2025)

11.2.1.      North America Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.1.1. United States Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.1.2. Canada Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.1.3. Mexico Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.2.      Europe Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.2.1. Germany Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.2.2. France Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.2.3. UK Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.2.4. Russia Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.2.5. Italy Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.2.6. Rest of Europe Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.3.      Asia-Pacific Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.3.1. China Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.3.2. Japan Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.3.3. Korea Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.3.4. India Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.3.5. Southeast Asia Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.3.6. Rest of Asia-Pacific Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.4.      South America Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.4.1. Brazil Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.4.2. Argentina Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.4.3. Columbia Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.4.4. Rest of South America Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.5.      Middle East and Africa Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.5.1. Saudi Arabia Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.5.2. United Arab Emirates Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.5.3. Egypt Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.5.4. Nigeria Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.5.5. South Africa Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.5.6. Turkey Dilated Cardiomyopathy Market Forecast (2018-2025)

11.2.5.7. Rest of Middle East and Africa Dilated Cardiomyopathy Market Forecast (2018-2025)

11.3. Dilated Cardiomyopathy Market Forecast by Drug Class (2018-2025)

11.3.1.      Dilated Cardiomyopathy Forecast by Drug Class (2018-2025)

11.3.2.      Dilated Cardiomyopathy Market Share Forecast by Drug Class (2018-2025)

11.4. Dilated Cardiomyopathy Market Forecast by Device (2018-2025)

11.4.1.      Dilated Cardiomyopathy Forecast by Device (2018-2025)

11.4.2.      Dilated Cardiomyopathy Market Share Forecast by Device (2018-2025)

11.5. Dilated Cardiomyopathy Market Forecast by Distribution Channel (2018-2025)

11.5.1.      Dilated Cardiomyopathy Forecast by Distribution Channel (2018-2025)

11.5.2.      Dilated Cardiomyopathy Market Share Forecast by Distribution Channel (2018-2025)

 

12.    List of Tables and Figures

Figure United States Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Canada Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Mexico Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Germany Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure France Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure UK Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Russia Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Italy Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Rest of Europe Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure China Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Japan Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Korea Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure India Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Southeast Asia Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Rest of Asia-Pacific Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Brazil Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Argentina Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Columbia Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Rest of South America Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Saudi Arabia Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure United Arab Emirates Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Egypt Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Nigeria Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure South Africa Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Turkey Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Figure Rest of Middle East and Africa Dilated Cardiomyopathy Revenue (Million USD) and Growth Rate (2014-2025)

Table Global Dilated Cardiomyopathy Revenue and Revenue Share by Drug Class (2014-2018)

Figure Global Cardiac Glycosides Revenue and Growth Rate (2014-2018)

Figure Global Beta Blockers Revenue and Growth Rate (2014-2018)

Figure Global Angiotensin-Converting Enzyme (ACE) Inhibitors Revenue and Growth Rate (2014-2018)

Figure Global Blood Thinning Medications Revenue and Growth Rate (2014-2018)

Figure Global Diuretics Revenue and Growth Rate (2014-2018)

Figure Global Angiotensin II Receptor Blockers Revenue and Growth Rate (2014-2018)

Table Global Dilated Cardiomyopathy Revenue and Revenue Share by Device (2014-2018)

Figure Global Heart Pumps Revenue and Growth Rate (2014-2018)

Figure Global Cardioverter-Defibrilators Revenue and Growth Rate (2014-2018)

Figure Global Implantable Devices Revenue and Growth Rate (2014-2018)

Table Global Dilated Cardiomyopathy Revenue and Revenue Share by Distribution Channel (2014-2018)

Figure Global Hospital Pharmacies Revenue and Growth Rate (2014-2018)

Figure Global Mail Order Pharmacies Revenue and Growth Rate (2014-2018)

Figure Global Retails Pharmacies Revenue and Growth Rate (2014-2018)

Figure Global Online Pharmacies Revenue and Growth Rate (2014-2018)

Table Global Dilated Cardiomyopathy Revenue by Regions (2014-2018)

Figure North America Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure North America Dilated Cardiomyopathy Revenue and Growth Rate (2014-2018)

Figure North America Dilated Cardiomyopathy by Countries (2014-2018)

Figure North America Dilated Cardiomyopathy Revenue (Million USD) by Countries (2014-2018)

Figure United States Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure United States Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Canada Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Canada Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Mexico Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Mexico Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Europe Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Europe Dilated Cardiomyopathy Revenue and Growth Rate (2014-2018)

Figure Europe Dilated Cardiomyopathy by Countries (2014-2018)

Figure Europe Dilated Cardiomyopathy Revenue (Million USD) by Countries (2014-2018)

Figure Germany Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Germany Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure France Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure France Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure UK Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure UK Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Russia Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Russia Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Italy Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Italy Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Rest of Europe Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Rest of Europe Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Asia-Pacific Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Asia-Pacific Dilated Cardiomyopathy Revenue and Growth Rate (2014-2018)

Figure Asia-Pacific Dilated Cardiomyopathy by Countries (2014-2018)

Figure Asia-Pacific Dilated Cardiomyopathy Revenue (Million USD) by Countries (2014-2018)

Figure China Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure China Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Japan Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Japan Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Korea Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Korea Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure India Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure India Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Southeast Asia Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Southeast Asia Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Rest of Asia-Pacific Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Rest of Asia-Pacific Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure South America Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure South America Dilated Cardiomyopathy Revenue and Growth Rate (2014-2018)

Figure South America Dilated Cardiomyopathy by Countries (2014-2018)

Figure South America Dilated Cardiomyopathy Revenue (Million USD) by Countries (2014-2018)

Figure Brazil Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Brazil Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Argentina Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Argentina Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Columbia Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Columbia Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Rest of South America Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Rest of South America Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Middle East and Africa Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Middle East and Africa Dilated Cardiomyopathy Revenue and Growth Rate (2014-2018)

Figure Middle East and Africa Dilated Cardiomyopathy by Countries (2014-2018)

Figure Middle East and Africa Dilated Cardiomyopathy Revenue (Million USD) by Countries (2014-2018)

Figure Saudi Arabia Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Saudi Arabia Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure United Arab Emirates Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure United Arab Emirates Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Egypt Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Egypt Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Nigeria Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Nigeria Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure South Africa Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure South Africa Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Turkey Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Turkey Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Figure Rest of Middle East and Africa Dilated Cardiomyopathy Growth Rate (2014-2018)

Figure Rest of Middle East and Africa Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2014-2018)

Table Johnson and Johnson  Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Merck & Co. Inc.  Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Zensun Sci & tech  Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Capricor Therapeutics Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Sanofi Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Teva Pharmaceuticals  Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Array BioPharma  Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Aastrom Biosciences Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Vericel Corporation Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table t2cure GmbH Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table MyoKardia  Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table GlaxoSmithKline plc. Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Kasiak Research Pvt. Ltd.  Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Pfizer Inc. Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Astrazeneca plc. Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Table PhaseBio Pharmaceuticals  Dilated Cardiomyopathy Price, Revenue, Gross Margin and Market Share (2016-2017)

Figure Global Dilated Cardiomyopathy Market Share by Manufacturer

Figure Global Dilated Cardiomyopathy Revenue and Market Share by Manufacturer

Table Global Dilated Cardiomyopathy Price by Region (2016-2017)

Figure Top 5 Dilated Cardiomyopathy Manufacturer (Revenue) Market Share

Figure Market Competition Trend

Figure     Global Dilated Cardiomyopathy Revenue (Millions USD) and Growth Rate (2018-2025)

Table Dilated Cardiomyopathy Market Forecast by Regions (2018-2025)

Figure North America Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure United States Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Canada Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Mexico Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Europe Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Germany Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure France Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure UK Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Russia Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Italy Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Rest of Europe Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Asia-Pacific Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure China Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Japan Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Korea Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure India Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Southeast Asia Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Rest of Asia-Pacific Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure South America Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Brazil Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Argentina Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Columbia Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Rest of South America Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Middle East and Africa Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Saudi Arabia Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure United Arab Emirates Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Egypt Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Nigeria Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure South Africa Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Turkey Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Rest of Middle East and Africa Dilated Cardiomyopathy Market Forecast (2018-2025)

Figure Global Dilated Cardiomyopathy Forecast by Drug Class (2018-2025)

Figure Global Dilated Cardiomyopathy Market Share Forecast by Drug Class (2018-2025)

Figure Global Dilated Cardiomyopathy Forecast by  Drug Class (2018-2025)

Figure Global Dilated Cardiomyopathy Forecast by Device (2018-2025)

Figure Global Dilated Cardiomyopathy Market Share Forecast by Device (2018-2025)

Figure Global Dilated Cardiomyopathy Forecast by  Device (2018-2025)

Figure Global Dilated Cardiomyopathy Forecast by Distribution Channel (2018-2025)

Figure Global Dilated Cardiomyopathy Market Share Forecast by Distribution Channel (2018-2025)

Figure Global Dilated Cardiomyopathy Forecast by  Distribution Channel (2018-2025)


Please Note: Data related to the Companies are subject to Availability.

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*